In mice, active protection against Pseudomonas aeruginosa could be induced with two fractions derived from a crude preparation of ribosomes from P. aeruginosa. The two fractions were obtained by gel filtration chromatography of the crude ribosomal preparation on Sepharose CL-2B. In fraction I, less than 1% of the ribonucleic acid (RNA) applied to the column was recovered. Fraction II contained RNA and protein in a ratio of 1.94. The presence of ribosomes in this fraction was confirmed by analysis on a sucrose density gradient. The protection by fraction I was not affected by treatment with ribonuclease; in contrast, incubation of fraction II with ribonuclease completely abolished active protection. Fraction I contained lipopolysaccharide (LPS) as was indicated by the presence of 2-keto-3-deoxyoctonic acid. No LPS was found in fraction II. The adjuvant dimethyl dioctadecyl ammonium bromide enhanced the protection by fraction II; however, immunity by a low dose of fraction I was abolished by dimethyl dioctadecyl ammonium bromide. Protection by fractions I and II appeared to be restricted to the homologous serotype of P. aeruginosa. These results indicate that RNA is required for protection by fraction II. Active protection by fraction
In mice, active protection against Pseudomonas aeruginosa could be induced with two fractions derived from a crude preparation of ribosomes from P. aeruginosa. The two fractions were obtained by gel filtration chromatography of the crude ribosomal preparation on Sepharose CL-2B. In fraction I, less than 1% of the ribonucleic acid (RNA) applied to the column was recovered. Fraction II contained RNA and protein in a ratio of 1.94 . The presence of ribosomes in this fraction was confirmed by analysis on a sucrose density gradient. The protection by fraction I was not affected by treatment with ribonuclease; in contrast, incubation of fraction II with ribonuclease completely abolished active protection. Fraction I contained lipopolysaccharide (LPS) as was indicated by the presence of 2-keto-3-deoxyoctonic acid. No LPS was found in fraction II. The adjuvant dimethyl dioctadecyl ammonium bromide enhanced the protection by fraction II; however, immunity by a low dose of fraction I was abolished by dimethyl dioctadecyl ammonium bromide. Protection by fractions I and II appeared to be restricted to the homologous serotype of P. aeruginosa. These results indicate that RNA is required for protection by fraction II. Active protection by fraction I is likely due to LPS.
Infections with antibiotic-resistant Pseudomonas aeruginosa remain a serious problem for compromised patients, such as burn patients, patients with malignancies, and children with cystic fibrosis. Clinical trials with vaccines containing lipopolysaccharide (LPS) of P. aeruginosa have indicated that burn patients may be protected from Pseudomonas bacteremia by active immunization (1) . However, vaccination with these preparations is associated with a high incidence of side effects (14) probably due to the toxicity of LPS.
In 1965 Youmans and Youmans (22) reported that ribosomal preparations of Mycobacterium tuberculosis could be highly immunogenic. Since then, ribosomal vaccines have been prepared from many bacterial species (6), including P. aeruginosa (12, 18) . Ribosomal vaccines of several microorganisms (e.g., M. tuberculosis, Salmonella typhimurium, Streptococcus pneumoniae) showed advantages over more conventional vaccines. The ability of the pneumococcal ribosomal vaccine to induce protection against other serotypes is of special interest (4). The immunogenic principle of the ribosomal vaccines has not been clarified. Youmans and Youmans (23) concluded that ribonucleic acid (RNA) of M. tuberculosis is the effective immunogen. Swendsen and Johnson (19) reported that ribosomal protein of S. pneumoniae is required, and Feit and Tewari (7) showed that both RNA and protein of Histoplasma capsulatum were necessary for protection. In the case of Vibrio cholerae, Jensen et al. (11) showed that an exogenous contaminant in ribosomal vaccines of V. cholerae was responsible for immunity. Andron et al. (2) have suggested that ribosomal RNA of Francisella tularensis plays a structural or a carrier role in the presentation of a somatic antigen.
The type of immunity may depend on the microorganism from which the ribosomal vaccine was prepared. A humoral immunity was evoked by vaccination with ribosomal vaccines prepared from S. pneumoniae, whereas ribosomal vaccines of S. typhimurium were reported to induce cellular immunity (6) .
Ribosomal vaccines of P. aeruginosa have been described by several investigators (12, 18) . Lieberman (12, 13) reported that serum-mediated protection could be obtained with purified ribosomes. The protective capacity of this ribosomal vaccine was not diminished after treatment with ribonuclease (RNase) or trypsin (12) . In addition, Lieberman (13) did not find evidence for the presence of LPS because antibodies induced by the purified ribosomal vaccine in rabbits did not agglutinate LPS.
In the present paper we present evidence that active protection in mice against P. aeruginosa with a purified ribosomal vaccine is dependent on RNA.
MATERIALS AND METHODS Bacteria. P. aeruginosa serotypes 3 and 8 (strains RIV 76-5321 and 76-5309, respectively) were kindly provided by J. Borst, National Institute of Public Health, Bilthoven, The Netherlands. These strains were isolated from clinical specimens in 1976. Suspensions of bacteria were stored in small portions at -700C. Strain RIV 76-5321 (serotype 3) was used in all experiments as the challenging organism and for the preparation of the vaccines, except in the experiments concerning the specificity of protection.
Mice. Outbred male and female Cpb SE Swiss mice (body-weight 18 to 20 g) were purchased from TNO, Central Institute for the Breeding of Laboratory Animals, Zeist, The Netherlands.
Crude ribosomal preparation from P. aeruginoa8L Bacteria were grown in 8 A part of the filtered fraction I was stored in small portions, and another part was lyophilized, resuspended at a concentration of 10 mg (dry weight)/ml, and stored at -70°C. The pellet of fraction II was suspended at a concentration of 50 mg (wet weight)/ ml in TKM buffer and filtered through a 0.2-,tm Sartorius filter. A part of the filtered fraction II was stored at -70°C, and another part was lyophilized, resuspended at a concentration of 10 mg (dry weight)/ml, and stored at -70°C.
Sterility. Sterility of all vaccines was insured by inoculating tubes (Trypticase soy broth) and plates (Trypticase soy agar) with a drop of the vaccine. If there was no growth after 48 h, the vaccine was considered to be sterile.
Chemical analyses. The amount of deoxyribonucleic acid (DNA) was determined by the diphenylamine method of Dische, according to the modification of Burton (5) with calf thymus DNA (Merck) as the standard. The amount of RNA was estimated by the orcinol method of Herbert et al. (9), using yeast RNA (Boehringer Mannheim Corp., Mannheim, West Germany) as the standard. The concentration of protein was determined by the Folin method modified by Hartree (8) with bovine serum albumin as the standard. The amount of phospholipid was determined as follows (16) . Fraction I was dialyzed against 0.005 M Tris buffer (pH 7.0) to remove the excess of sodium dodecyl sulfate. Samples (1 ml) of the crude ribosomal preparation and of fractions I and II containing 2, 2, and 5 mg (dry weight), respectively, were extracted three times with 3.75 ml of a mixture of methanol and chloroform (2:1 vol/vol) and centrifuged. The combined supernatants were dried under nitrogen at 37°C. The residues were extracted three times with 3 ml of chloroform. The combined supernatants were dried under nitrogen at 37°C, and the residues were hydrolyzed at 180°C with 0.5 ml of 72% perchloric acid until the digest was colorless. The hydrolysate was cooled to room temperature, and 4.1 ml of distilled water, 0.2 ml of 5% ammonium molybdate, and 0.2 ml of Fiske Subbarow reagent were added. The mixture was heated for 15 
RESULTS
Molecular sieve chromatography of the crude ribosomal preparation. The crude ribosomal preparation was further purified on Sephadex CL-2B. Two distinct peaks were obtained (Fig. 1) . Fraction I (turbid) eluted in the void volume, whereas fraction II was retarded.
Composition of crude ribosomal preparation, fractions I and II. The amount of DNA, RNA, protein, phospholipid, and LPS per milligram (dry weight) and the ratio of RNA to protein of the crude ribosomal preparation, fractions I and II, are presented in Table 1 . The recovery of these constituents of the crude ribosomal preparation after molecular sieve chromatography is shown in (Fig. 2B ) and in the crude ribosomal preparation (Fig. 2A) . In the presence of 1 mM MgCl2, the 70S ribosomes dissociated into the 50S and 30S subunits.
Fraction II contained 8 ,ug of phospholipid/mg (dry weight) and less than 0.8 ,g of LPS/mg (dry weight). In contrast, fraction I contained 98
Mg of LPS/mg (dry weight) and 76 ,ug of phospholipid/mg (dry weight). Of the RNA in the crude ribosomal preparation only 0.7% was recovered in fraction I ( (14) , ribosomal vaccines might offer a nontoxic alternative preventing the compromised patient from becoming infected with this organism (3). Although effective ribosomal vaccines are prepared from many microorganisms, the immunogenic principle of these vaccines has not been fully clarified. The discus- sion on the nature of ribosomal vaccines focuses on whether the immunogenicity of these vaccines is due to an exogenous contaminant or is caused by the ribosomes. The present study provides evidence that the protection by a purified ribosomal vaccine of P. aeruginosa is dependent on the presence of RNA.
A crude ribosomal preparation of P. aeruginosa was separated into two fractions by molecular sieve chromatography. The first one, fraction I, contained high-molecular-weight or aggregated material in which protein, phospholipid, and LPS were present. Less than 1% of the total RNA was recovered in this fraction. Pre Treatment of fraction II with RNase completely abolished the protection, whereas this enzyme did not affect the protection by fraction I. Treatment with pronase and trypsin did not significantly alter the protection by fraction I or II. These results indicate that the protection by fraction II was dependent on the presence of RNA. Second, the adjuvant DDA enhanced the immunity induced by fraction II. In contrast, the protection by a low dose of fraction I was abolished by this adjuvant. Therefore, it seems unlikely that the protection by fraction II is due to a contamination with substances present in fraction I.
Since RNA is indispensable for protection by fraction II, RNA might be the immunogen of this fraction. Alternatively, RNA could exert an immunomodulating effect on an unidentified, protease-resistant component in fraction II. The latter hypothesis includes the possibility that a nonimmunizing trace of cell envelope components in fraction II becomes protective by the adjuvant activity of the ribosomal RNA. It is interesting that fraction II did not induce protection against a heterologous challenge.
Several authors (12, 18) have described ribosomal vaccines of P. aeruginosa. Interesting results were reported by Lieberman et al. (12, 13) . These authors separated a ribosomal preparation of P. aeruginosa into two fractions by molecular sieve chromatography on Sepharose CL-4B. Both fractions consisted mainly of RNA and protein. In contrast to the results presented in this paper, the protection induced by their second fraction ("peak B"), containing purified ribosomes, was not affected by treatment with RNase. These data indicate that the protection obtained by purified ribosomes is not due to an RNA-dependent immunogen. In-addition, Lieberman et al. (12, 13) demonstrated that protection by the purified ribosomal vaccine is also not due to contaminating LPS. The reasons that the protection by the purified ribosomal preparation of Lieberman et al. (12) is RNA independent and that the protection of our purified ribosomal vaccine is RNA dependent could be because different P. aeruginosa strains were used, the purification procedures were not the same, Lieberman et al. used a higher challenge dose, or all of these. It is unlikely that the conflicting observations could be due to the mouse strains used, since we also obtained protection with fraction II in C57BL/10 mice (data not shown).
